Abstract
Molecular target-based drugs have been expected as promising drugs in cancer treatment, and clinical trials using combined radiation therapy plus molecular target-based drugs have been performed to evaluate the feasibility and efficacy of this approach. In order to obtain maximum radiotherapeutic gain, a detailed understanding of the mechanism underlying the interaction between radiation and these drugs is indispensable. Preclinical data have already demonstrated synergistic enhancement of radiation-induced cell killing by several molecular target-based drugs, such as EGFR inhibitors. Among these, the effect of drugs targeted against receptor tyrosine kinase and its signal transduction pathways on the radiosensitivity has been intensively investigated. In this review, established and potential molecular targets for potentiation of radiation-induced cell killing are summarized, especially focusing on EGFR and its signal transduction pathways; also, clinical trials of combined radiation therapy plus molecular-target drug therapy are summarized.
Keywords: EGFR, molecular target, radiation, radiosensitivity
Current Signal Transduction Therapy
Title: Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Volume: 5 Issue: 3
Author(s): Tetsuo Akimoto and Norio Mitsuhashi
Affiliation:
Keywords: EGFR, molecular target, radiation, radiosensitivity
Abstract: Molecular target-based drugs have been expected as promising drugs in cancer treatment, and clinical trials using combined radiation therapy plus molecular target-based drugs have been performed to evaluate the feasibility and efficacy of this approach. In order to obtain maximum radiotherapeutic gain, a detailed understanding of the mechanism underlying the interaction between radiation and these drugs is indispensable. Preclinical data have already demonstrated synergistic enhancement of radiation-induced cell killing by several molecular target-based drugs, such as EGFR inhibitors. Among these, the effect of drugs targeted against receptor tyrosine kinase and its signal transduction pathways on the radiosensitivity has been intensively investigated. In this review, established and potential molecular targets for potentiation of radiation-induced cell killing are summarized, especially focusing on EGFR and its signal transduction pathways; also, clinical trials of combined radiation therapy plus molecular-target drug therapy are summarized.
Export Options
About this article
Cite this article as:
Akimoto Tetsuo and Mitsuhashi Norio, Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes, Current Signal Transduction Therapy 2010; 5(3) . https://dx.doi.org/10.2174/157436210791920274
DOI https://dx.doi.org/10.2174/157436210791920274 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meet Our Editorial Board Member
Current Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8
Anti-Cancer Agents in Medicinal Chemistry Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets Idiopathic Pulmonary Fibrosis: Treatment Strategies
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry The Extracapsular Lymph Node Extension Predicts Outcomes in Colorectal Cancer: A Short Review
Current Drug Targets Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Targeting Trail Towards the Clinic
Current Drug Targets Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry